Early Phase Cancer Immunotherapy (Current Cancer Research) - Hardcover

Hardcover

ISBN 10: 3319637568 ISBN 13: 9783319637563

Verlag: Springer, 2017

Inhaltsangabe

This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.

Über diesen Titel

Über die Autorin bzw. den Autor

Razelle Kurzrock, MD, is Senior Deputy Director for Clinical Science, Chief, Division of Hematology & Oncology, Murray Professor of Medicine, Director, Center for Personalized Cancer Therapy & Clinical Trials Office, University of California, San Diego.

Sandip Patel, MD, is Assistant Professor, Cancer Immunotherapy Program, Experimental Therapeutics (Phase 1 Program), Thoracic Oncology, Division of Hematology & Oncology and Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center.

Von der hinteren Coverseite

This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.

Details zur Ausgabe

• Verlag: Springer
• Erscheinungsdatum: 2017
• Sprache: Englisch
• ISBN 10: 3319637568
• ISBN 13: 9783319637563
• Einband: Gebundene Ausgabe
• Auflage: 1
• Anzahl der Seiten: 342
• Herausgeber: Patel Sandip Pravin, Kurzrock Razelle
• Kontakt zum Hersteller: Springer Nature Customer Service Center GmbH; ProductSafety@springernature.com; ; Europaplatz 3; Heidelberg; 69115; Deutschland